1) Histopathologically confirmed colorectal cancer (The primary tumor of an appendix, and an anal canal and the anus is excluded) 2) Unresectable progress recurrence colon cancer 3) Metastatic colorectal cancer which has prior therapy of Oxaliplatin based chemotherapy. But, if it is the recurrence at less than 180 Days after the end of chemotherapy which contains LOHP as a postoperative adjuvant chemotherapy is enforced, it is considered as the object of the examination 4) No prior chemotherapy of CPT11 5) KRAS mutant type 6) The presence of evaluable disease based on the recist criterion. (within 30 days before registration) 7) Adequate organ functions (within 7 days before registration) Leu>3000/mm3, <12000/mm3, Neu>1500 /mm3, Plt>100000 /mm3, Hemoglobin>9.0 g/dL, ALT<ULNx2.5, AST<ULNx2.5, Total.bil<ULNx1.5, Ccr or eGFR>60 ml/min, 8) Age>20, 9)Performance Status (ECOG) 0 to 1, 10) Oral intake possible, 11) Expected more than 3 months survival, 12) With written informed consent

Key exclusion criteria

1)Presence of active multiple primaries.
Active multiple primaries is simultaneous or metachronous with disease-free interval of 5 years or more. But, carcinoma in situ and skin cancer which are judged to be recovery by medical treatment are excluded.
2)Massive pleural effusion or ascites that required drainage
3)Symptomatic brain meta
4)Severe psychiatric disease or psychiatric symptoms
5)Severe complications
6)Undertook radiation therapy for abdominal lesions
7)History of serious drug hypersensitivity or a history of drug allergy
8)Pregnant or lactating woman
9)Requiring steroid drug
10)Receiving flucytosine, atazanavir sulfate
11)Uncontrollable diarrhea 12)Uncontrollable peptic ulcer
13)High-grade peritoneal metastasis and stricture
14)History of the perforation of the digestive tract within 6 months before registration
15)History of the thromboembolism, brain infarction, lung infarction, brain infarction or pneumonitis
16)Operation within 28 days
17)Congenital bleeding predisponency or abnormality of hemostasis
18)Patients have anticoagulant agent
19)Not appropriate for the study at the physician's assessment

Target sample size

30

Research contact person

Name of lead principal investigator

1st name

Middle name

Last name

Shoichi Hazama

Organization

Yamaguchi University

Division name

Department of Digestive Surgery and Surgical Oncology

Zip code

Address

1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan

TEL

+81-836-22-2264

Email

hazama@yamaguchi-u.ac.jp

Public contact

Name of contact person

1st name

Middle name

Last name

Shoichi Hazama

Organization

YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE

Division name

Department of Digestive Surgery and Surgical Oncology

Zip code

Address

1-1-1 Minamikogushi , Ube, 755-8505, Japan

TEL

81-836-22-2264

Homepage URL

Email

hazama@yamaguchi-u.ac.jp

Sponsor

Institute

Yamaguchi University
Department of Digestive Surgery and Surgical Oncology

Institute

Department

Funding Source

Organization

Yamaguchi University
Department of Digestive Surgery and Surgical Oncology